RIO DE JANEIRO, BRAZIL - A scientific paper in preprint (not yet peer-reviewed) points out that the efficacy of Coronavac against Covid-19 is higher than previously reported. The so-called primary efficacy, which represents the vaccine's protection against the disease at any intensity, increased from 50.38% to 50.7%, reaching 62.3% with longer intervals between doses. Against moderate cases, the immunization is 83.7% effective, when the previous data indicated 78%.
The information is contained in an article prepared by the professionals who conducted the Coronavac tests in Brazil, led by the Butantan Institute. The document . . .
To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed? Login Here